Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-agent nab-paclitaxel for metastatic pancreatic cancer
ChiCTR2000034360Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: 6-month overall survival rate, overall survival (OS) and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2000034360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034360.